Genzyme Ventures reboot

After a slow integration period, Sanofi-Genzyme BioVenturesis looking to make up to five investments per year in early stage companies that align with the focus of parent Sanofi (Euronext:SAN; NYSE:SNY). The goal is to bolster the pharma's pipeline in rare diseases, oncology and vaccines.

Sanofi did not have its own corporate venture fund when it acquired Genzyme Corp. in April 2011 and gained Genzyme Ventures, now SGBV...